Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   fibrinogen on the move.

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,856   -0,020   (-2,23%) Dagrange 0,837 - 0,880 9.028.873   Gem. (3M) 5,8M

fibrinogen on the move.

Volgen
211 Posts
Pagina: 1 2 3 4 5 6 ... 11 »» | Laatste | Omlaag ↓
  1. jurpsy 26 augustus 2006 11:09
    Cows that Could Save Lives

    While developing his hemophilia treatment, Chemical and Biomolecular Engineering Professor
    William Velander discovered that genetically engineered fibrinogen made in milk could
    fill a shortage of human plasma.
    He rejected cow milk as a potential source of hemophilia proteins because the cow protein
    contains a signature that causes it to die shortly after being infused into the human body.
    However, fibrinogen is masterful at clotting wounds while acting topically. With help from the
    American Red Cross and Pharming NV, a decade ago Velander began making transgenic cows
    that produce genetically engineered fibrinogen in their milk.

    He incorporates the fibrinogen into a heavy-duty bandage that stops bleeding on contact.
    “When you put that much clotting power in the palm of your hand, it’s so powerful that you can
    hear the wound gushing,” Velander said.
    One can make a fibrinogen bandage from the protein in human plasma, but it’s difficult to
    obtain large amounts of the protein. On the other hand, milk from transgenic cows contains an
    abundant supply. That means an animal-based fibrinogen bandage can be mass-produced at a
    relatively low cost.
    Because hemorrhaging causes 50 percent of war casualties, the bandage is a needed tool for
    treating battle wounds. The U.S. Army gave Velander a $3 million grant to mass-produce the
    bandage for military use. Velander’s goal is to increase production from 100,000 bandages annually
    to millions. That would satisfy the military’s needs, plus make the bandage available to
    paramedics and surgeons. “It has already been tested in Iraq and has saved lives,” Velander said.

    www.engineering.unl.edu/publications/...
  2. jurpsy 26 augustus 2006 11:11
    ......"Velander’s goal is to increase production from 100,000 bandages annually
    to millions. That would satisfy the military’s needs, plus make the bandage available to
    paramedics and surgeons.""""""""" “It has already been tested in Iraq and has saved lives,” """""""!!!!!!!!!!!Velander said.

    ..The U.S. Army gave Velander a $3 million grant to mass-produce the
    bandage for military use.

    DOD-Army Medical Research 8/1/05

    Proposed Duration .... Dollar Support

    2/1/07............................$3,044,606

    begin 2007 uitsluitsel ?--)))
  4. [verwijderd] 26 augustus 2006 12:25
    potdomme, loopt het zo maar onder ons uit.
    Dit is al geschreven in de lente van 2006, en ik zie het nu pas voor het eerst.
    Dit is ook de eerste keer dat ik zie dat de US army blijkbaar al veel meer stappen heeft gezet dan ik had aangenomen.
    Goed gevonden, compliments, en aanbevolen.

    alfa
  9. [verwijderd] 26 augustus 2006 17:10
    William H. Velander

    Biography

    William H. Velander is the W. Martin Johnson Professor of Engineering at Virginia Polytechnic Institute and State University. He has been working on safer, abundant sources of blood derived medicines since 1987, when the advent of disease contamination of blood derived medicines by HIV, Hepatitis B and C reached a world-wide epidemic. To help reduce that risk, Dr. Velander has jointly with the American Red Cross pioneered genetically engineered versions of human anticoagulant Protein C, human anti-hemophiliac factors VIII and IX, and fibrin glue precursor (for treating bleeding, tissue reconstruction and site specific drug delivery) from the milk of transgenic livestock. His work on using this technology to promote hemophilia treatment in lesser developed countries is currently touted by the World Federation of Hemophilia (WFH), a United Nations NGO. He was an invited speaker at the XXV International Congress of the WFH, Seville Spain, May 19-24, 2002. His group also helped pioneer efforts in humanizing pig tissue to provide stop-gap alternatives for organ transplants.

    Dr. Velander's work on transgenic animals is known worldwide in scientific literature such as Proceedings of the National Academy of Science and Nature as well as through international media including CNN's Future Watch, RAI's Quark, The New York Times, The Wall Street Journal, The London Daily Telegraph, the cover story of October 1999 National Geographic, May 1998 Discover, July 1998 Smithsonian and the January 1997 issue of Scientific American. His work with hemophilia factors was featured on the Discovery Health Channel in November 2001. Dr. Velander was instrumental in the formulation of federal regulatory guidelines for pharmaceuticals derived from transgenic animals through his consultancy with the FDA. He is a co-inventor of 7 US patents concerning gene transfer and the production of biopharmaceuticals whereupon all have been licensed and are in the process of commercialization. Dr. Velander is a fellow of the American Institute of Medical and Bioengineering.

    Dr. Velander earned his B.S. in Biochemistry from Illinois Benedictine College, Lisle; his M.ChE. in Chemical Engineering from Illinois Institute of Technology, Chicago; and his Ph.D. in Chemical Engineering from The Pennsylvania State University.

  10. [verwijderd] 26 augustus 2006 17:14
    Dr. William H. Velander

    Dr. Velander has been the Chair of the Chemical and Biomolecular Engineering Department at the University of Nebraska-Lincoln since 2003. He was awarded the D.R. Voelte and N.A. Keegan Endowed Chair in Engineering in 2004. He is a member of several esteemed organizations such as the American Institute of Medical and Bioengineering and American Chemical Society.

    Research Interests:
    Dr. Velander has been working on safer, abundant sources of plasma-derived medicines since 1987, when disease contamination of blood supply medicines by HIV, Hepatitis B and C reached a world-wide epidemic. To help reduce that risk, Dr. Velander has jointly with the American Red Cross Holland Laboratory pioneered genetically engineered versions of human anticoagulant Protein C, human anti-hemophiliac factors VIII and IX, and fibrinogen (for fibrin glue precursor for hemostatic devices, tissue reconstruction and site specific drug delivery) from the milk of transgenic livestock. Dr. Velander’s group also helped in pioneering efforts to humanize pig tissue to provide stop-gap alternatives for organ transplants.

    Dr. Velander's work on transgenic animals is known worldwide in scientific literature such as the Proceedings of the National Academy of Science and Nature Biotechnology as well as through international media including CNN's Future Watch, RAI's Quark, The New York Times, The Wall Street Journal, The London Daily Telegraph, the cover story of October 1999 National Geographic, May 1998 Discover, July 1998 Smithsonian and the January 1997 issue of Scientific American. His work with hemophilia factors was featured on "21st Century Medicine: Genetic Promises" on the Discovery Health Channel in November 2001 and also in the exhibit 'Engineering Genes' at the Museum of Science and Industry in Chicago, Illinois. Dr. Velander is an elected fellow of the American Institute for Medical and Bioengineering. Dr. Velander was instrumental in the formulation of federal regulatory guidelines for human therapeutics derived from transgenic animals through his consultancy with the USFDA. He is a co-inventor of several US patents concerning the production of recombinant proteins of haemostasis.

    Current Funding:
    Dr. Velander is currently the principal investigator of a $10M, 5 year NIH grant awarded to the University of Nebraska-Lincoln in September 2005 for research on recombinant hemophilia factors. He is also the principal investigator of a $3M grant from the USARMY for the production of a fibrinogen haemostatic bandage.

    Invited talks Selected from the Last Five Years:
    "Transgenic Technology for Factor IX", March 17, 2006 B. V. Patel Pharmaceutical Education and Research Development Center, Thaltej, Ahmedabad, India

    "Complex Post-translational Modifications of Biotherapeutics by Mammary Epithelia: Matching the Best Production Characteristics to a Given Transgenic Livestock", November 22, 2005 Novo Nordisk A/S, Novo Nordisk Park, Måløv, Denmark

    "Producing complex glycoprotein of hemostasis using transgenic livestock: enabling abundant and new therapeutic alternatives" Fifth Bari International Conference on Hemophilia and Allied Disorders, von Willebrand factor (including ADAMTS-13) and Platelet Glycoproteins May 22-25, 2005 Pizzomunno, Vieste del Gargano, Foggia, Italy

    "Hemophilic Factors Produced by Transgenic Livestock: Abundance That Can Enable Alternative Therapies Worldwide" in State of Art Plenary Lectures, XXVIth International Congress of The World Federation of Hemophilia, Bangkok Thailand, October 17-21, 2004.

    "Production of Biopharmaceuticals in the Milk of Pigs with Emphasis on Factor IX for Treatment of Hemophiliacs" in Emerging Trends in Genomics: Application and Approaches, "Animal Genomics Symposium 2003" October 9 & 10, 2003, Charles Hamner Conference Center, NC Biotechnology Center, 15 T.W. Alexander Drive, Research Triangle Park, NC

    "Production of Factor IX in Transgenic Animals", National Hemophilia Foundation Workshop on Gene Therapy April 26, 2003, The Salk Institute, La Jolla, CA

    "Transgenic Animals: Present Status of Technology and Future Applications" Biotechnology in the Barnyard, sponsored by PEW Foundation and USFDA, September 24, 2002, Dallas, Texas

    Recent Publications
    K. E. Van Cott, P. E. Monahan, T. Nichols, William H. Velander (2004) "Hemophilic Factors Produced by Transgenic Livestock: Abundance That Can Enable Alternative Therapies Worldwide", Hemophilia, 10: 70-76.

    S. P. Butler, T. K. O'Sickey, S.T. Lord, H. Lubon, F.C. Gwazdauskas, and W.H. Velander, "Secretion of Recombinant Human Fibrinogen by the Murine Mammary Gland" (2004) Transgenic Research, 13: 437-450.

    M. Lindsay, G. C. Gil, A. Cadiz, C. Zhang, W.H. Velander, K. E. Van Cott. Purification of Recombinant DNA-derived Factor IX and Fractionation of Active and Inactive Subpopulations. Journal of Chromatography, 1026:149-157.2004.

    LC Bolling, RS Pleasant, SP Butler, W.H. Velander and FC Gwazdauskas (2003) An Evaluation of Sperm Mediated Gene Transfer, Transgenics 4: 77-86.

    CA Schomotzer, SP Butler, RE Pearson, W.H. Velander, and FC Gwazdauskas (2003) Assessment of DNA Expression Following Cytoplasmic Microinjection of Condensed DNA into Murine Embryos Using Electropulsation, Transgenics, 4:55-63.

    W.H. Velander and Kevin Van Cott, Protein Expression Using Transgenic Animals, in Handbook of Industrial Cell Culture Mammalian, Microbial, and Plant Cells eds. Vinci, Victor A. and Parekh, Sarad R. , Human Press, Totawa NJ (2002).

    Van Cott KE, Lubon H, Gwazdauskas FC, Knight J, Drohan WN, W.H. Velander (2001). Recombinant Human Protein C Expression in the Milk of Transgenic Pigs and the Effect on Endogenous Milk Immunoglobulin and Transferrin Levels. Transgenic Research, 10: 43-51.

    Patents

    Transgenic non-human mammals producing fibrinogen in their milk issued January 10, 2006

    Transgenic non-human mammals expressing human coagulation factor VIII and von Willebrand factor US 6,518,482 issued February 11, 2003

    Expression of Active Human Factor IX in Mammary Tissue of Transgenic Animals US 09/367,087 issued February 5, 2002

    Transgenic Fibrinogen CA 2183546 issued August 21 2001

    Transgenic non-human mammals expressing human coagulation factor VIII and von Willebrand factor US 6,255,554 issued July 3, 2001

    Transgenic Animal Expressing Human Coagulation Factor VIII and Von Willebrand Factor US 08/308,518 issued March 9, 1999

    Expression of Active Human Protein C in the Mammary Tissue of Transgenic Animals Using A Long WAP Promoter US07/943246 issued November 1998.

    Expression of Active Human Protein C in the Mammary Tissue of Transgenic Animals US08/247 issued December 1996.
  12. [verwijderd] 26 augustus 2006 17:43
    quote:

    cees123 schreef:

    maar als ik het goed begrijp, heeft Pharming hier niets aan en wordt het door een ander gemaakt??

    "With help from the American Red Cross and Pharming NV, a decade ago Velander began making transgenic cows that produce genetically engineered fibrinogen in their milk."

    Vooralsnog neem ik aan dat dit project in samenwerking met Pharming gebeurt. Mocht dat niet zo zijn dan maakt hij in ieder geval gebruik van Pharming's techniek en patenten. Hoe dan ook zal Pharming hieraan verdienen.

    Groet,
    Tom
  13. jurpsy 26 augustus 2006 17:50
    quote:

    cees123 schreef:

    wie is Velander??
    MAJOR BIOTECH FIRM TO LOCATE IN SOUTHWEST
    VIRGINIA AND VIRGINIA TECH

    BLACKBURG, June 29, 1999 -

    - Pharming Healthcare Inc., the American subsidiary of Pharming Group N.V. of Leiden, Netherlands, will locate two unique pharmaceutical production installations in Southwest Virginia. A "transgenic" cattle farm in Craig County and purification facility at the Virginia Tech Corporate Research Center will comprise the first and second stages of its unique production line.

    Pharming, the world largest producer of transgenically produced pharmaceuticals, plans to invest about $37 million in Virginia to produce Human Factor VIII and Fibrinogen in the milk of transgenic animals[/i[i]. The company will produce supplies of these therapeutic blood clotting proteins to treat patients with hemophilia and control bleeding in surgery and trauma.

    In making this announcement with Virginia Governor James Gilmore, George J.M. Hersbach, chairman of Pharming Healthcare Inc. and president and CEO of Pharming Group NV, said "We have selected western Virginia for this phase of Pharming Healthcare’s growth because it offers an excellent infrastructure, including conditions to satisfy regulatory requirements for the manufacture of transgenically derived biopharmaceuticals."

    "Pharming is the world’s leader in this revolutionary concept of producing human medicine from animal milk. We are exceedingly pleased that they have chosen to locate in Virginia and at Virginia Tech. This is a testament to the university’s leadership on biotech applications," stated President Paul Torgersen.

    "Knowledge and intellectual capital are key ingredients to creating the jobs of tomorrow. This announcement demonstrates the real-world economic value of university research. We like to say at Virginia Tech that ‘we put knowledge to work.’ We are pleased to welcome Pharming to Virginia. "

    Pharming’s production techniques are partially based on technologies developed at Virginia Tech and licensed to the American Red Cross. Pharming has sublicensed the technology from the Red Cross.

    Virginia Tech’s research has lead to discoveries enabling biopharmaceutical production using transgenic livestock. Beginning with the ground breaking work of Dr. William Velander, professor of chemical engineering and director of the university’s Pharmaceutical Engineering Institute, the university has progressively increased the ability of the world’s scientific community to commercialize transgenic discoveries. Dr. Velander holds several patents on the development of therapeutic proteins.

    Pharming expects to employ about 88 people at its farm in Craig County and processing facility in Blacksburg. "These type of jobs are perfectly compatible with our region and with Virginia Tech. For the most part these high paying biotech jobs will require highly skilled individuals with advanced degrees," said John Phillips, Virginia Tech’s economic development officer.

    Phillips’ office works to bring the business community and university faculty together in projects that can create jobs. In this instance, the university worked behind the scenes for several years with regional and state economic development partners.

    The first stage for Pharming’s herd of transgenic cows will be at a farm in Craig County. The milk extract will be reprocessed at the Virginia Tech Corporate Research Center.

    Transgenic pharmaceutical production is based on a technique where a human protein is micro-injected into the embryo of another mammal such as a cow or pig. The protein becomes part of the animal’s genetic code. It is expressed in the animal’s milk and then extracted and reprocessed into a medicine for treatment of various human diseases.

    Currently, proteins and other molecules are purified from human blood or grown in cell cultures in enormous metal vats. Because of the threat of blood-borne diseases and amount of blood required to extract the proteins, the current process is very costly. Therefore, researchers are looking toward a new source of human protein pharmaceuticals.

    Scientific Contact:?Virginia Tech, William Velander, ?(O) 540-231-7869 ; (H) 540-953-1914

    W.Velander blijkt toch wel een belangrijke figuur voor Pharming....

    www.vtnews.vt.edu/Archives/1999/99276...

  16. [verwijderd] 26 augustus 2006 20:02
    Heel erg interessante stof!
    Moet ik nog eens goed bestuderen want in eerste instantie breekt me de klomp een beetje van verbazing.

    Een US patent uitgegeven op 10 januari 2006 dat omvat het doen produceren van fibrinogeen in de melk van niet-menselijke zoogdieren (bijv. koeien) met als gevolmachtigde Virginia Tech Intellectual Properties.Uitvinder o.a William Velander.

    Verder lezen we dat de US Army een donatie heeft gegeven van $3 miljoen om massaproductie van het fibrinogeen verband van Velander mogelijk te maken.
    Het verband wordt al geproduceerd in een oplage van 100000 stuks per jaar, is al getest in Irak en de bedoeling is de productie op te voeren naar miljoenen stuks per jaar!

    Wat heeft dit nu allemaal te betekenen??
    Is Virginia Tech/Velander op eigen houtje fibrinogeen verbanden aan het ontwikkelen èn verkopen?? Hebben zij hun oude patenten omtrent fibrinogeen winning uit de melk van o.a transgene koeien omgezet in een nieuw patent (zie hierboven?)*

    Wat impliceert dit nieuwe patent voor Pharming?
    Betekent het dat Pharming dat, gedeeltelijk van de patenten van Velander afhankelijk was/is, er nu een US Army concurrent bij heeft die via dezelfde technologie haar fibrinogeen produceert?? Een concurrent die bovendien gesubsidieerd wordt voor massaproductie terwijl Pharming geen vergoeding krijgt en de US Army naar mijn info de verbanden van Pharming op eigen kosten test. En nog steeds aan het testen zou zijn terwijl de fibrinogeen verbanden van Velander al in een oplage van 100000 stuks geleverd worden.
    Heeft de lange radiostilte van Pharming omtrent het fibrinogeen verband misschien met de ontwikkelingen van Velander van doen?
    En roep nou niet meteen: "bashersgedrag". Dit zijn voor mij vragen die oprijzen en bepaald nog niet definitief beantwoord zijn.

    Wie is er een beetje thuis in patenten?
    Groet Beur

    ps. Als Wijma hiervan op de hoogte was geweest had hij het vast vermeld in zijn artikeltje......

    *
    "Pharming’s production techniques are partially based on technologies developed at Virginia Tech and licensed to the American Red Cross. Pharming has sublicensed the technology from the Red Cross."
    www.vtnews.vt.edu/Archives/1999/99276...

  17. [verwijderd] 26 augustus 2006 20:32
    Een voor de hand liggend antwoord is natuurlijk dat Pharming de leverancier is van het fibrinogeen in het verband van Velander en aldus er de vruchten van plukt.
    Pharming heeft echter bij mijn weten nooit informatie verstrekt over een dergelijke, dus al lopende, verbintenis en op haar site spreekt Pharming van levering door haar zelf aan de US Army:

    "The United States Army will evaluate Pharming’s recombinant human fibrinogen (rhFIB) product. They will conduct studies using rhFIB to determine its use for various applications.
    Based on the outcome of these studies, Pharming will supply rhFIB to the US Army for tissue sealant as well as novel therapeutic applications. The two parties will execute a Cooperative Research and Development Agreement, which will define the extent of the collaboration upon successful evaluation of rhFIB."

    Prettig weekend! Beur
211 Posts
Pagina: 1 2 3 4 5 6 ... 11 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Vertrek CEO overschaduwt goede resultaten Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. Jefferies: positieve studiedata Pharming vergroten doelgroep Joenja
  2. AEX gaat vlakke opening tegemoet, Pharming en quantumchip Alphabet stelen de show
  3. Pharming meldt positieve studieresultaten met leniolisib
  4. Jefferies zet Pharming op de kooplijst
  5. CEO: volop groeimotoren voor Pharming
  6. AEX opent waarschijnlijk hóger op Super Thursday met Besi, Unilever en Pharming
  7. Topman De Vries stopt bij Pharming
  8. Pharming start met Fase II klinische studie leniolisib
  9. Pharming: herstelpotentieel van 100%
  10. Slotcall: BAM en Pharming vinden gretig aftrek op groen gekleurd Damrak